

Supplementary Table 1:

Demographic and Clinical Characteristics of Diabetic Patients				
Variable	Normal	Slow Progression <0.6cc/min/m	Fast >0.6cc/min/m	CKD5
	N=12	N=13	N=13	N=8
Male sex - no (%)	7(58)	5(38)	6(46)	3(37)
Age (years)	50.3±21.0 ^b	63.0±10.9 ^b	55.2±13.4 ^{b,d}	57.8±8 ^b
HTN	6(50)	13(100) ^a	13(100) ^a	8(100) ^a
DM	3(25)	13(100) ^b	13(100) ^b	8(100) ^b
ACE inhibitor or ARB	1(12.5)	9(69) ^b	10(76) ^b	5(100) ^b
Statin	4(33)	8(61) ^b	8(61) ^b	3(60)
Fibrate	0(0)	0(0)	0(0)	0(0)
BP on admision	126/75±26/12	151/81±16/10	151/86±24/13	161/81±8/8
Serum creatinine - mg/dl	0.9±0.3	1.5±0.5 ^{a,h}	2.1±1.3 ^{a,h}	5.2±1.1 ^a
Serum urea — mg/dl	39.2±14.7	73.3±20.3 ^{a,h}	85.6±44 ^{a,h}	169±57.9 ^{a,f}
Estimated GFR-ml/min/1.73m ²	97.4±29.5	46.8±20.3 ^{a,f}	51.4±36.1 ^{a,f}	10.4±3.2 ^{b,f}
Glycated hemoglobin %		7.4±1.3	9.0±2.5	9.7±3.7
Plasma LDL-c mg/dl	115.2±27.2	106.2±44.1	131.7±89.6	133.3±35.1
plasma-HDL-c mg/dl	51.7±17.1	49.8±12.0	52.6±18.8	40.1±14.9
plasma-TG mg/dl	154.0±66.4	355.8±449.4	243.7±215.9	161.0±31.3
Serum albumin - mg/dl	4.1±0.5	3.4±0.7 ^a	3.2±0.5 ^a	3.5±0.3 ^a
Proteinuria mg/day (median)	0	3000 ^a	6543 ^a	2900 ^a
weight kg	62.2±17.5	97.5±23.6	78.7±27.9	83±15.1
Histology				
glomeruli number	29.4±8.9	17.4±9.6 ^a	24.1±9.0	34.8±35.6
Globally sclerotic glomeruli(%)	1.9±3.0	23.8±20.4 ^a	35.9±28.7 ^a	49±35.6 ^a
Segmentally sclerotic glomeruli(%)	0.0	11.3±13.0 ^b	24.1±24.9 ^b	21.6±15.8 ^b
Increased mesangial matrix	0.3±0.4	1.6±0.8	2.1±0.7 ^b	2.2±0.8 ^b
Bowman's capsule thickening	0	1.9±0.4 ^b	1.7±0.5 ^b	2±0 ^b
Tubular atrophy (%)	0	1.4±0.5 ^b	1.7±0.5 ^b	2.2±0.8 ^b
Interstitial fibrosis (%)	0	1.2±0.6 ^{b,f}	1.5±0.5 ^{b,f}	2.1±0.6 ^b
Vascular sclerosis	0.1±0.35	1.5±0.8 ^{e,f}	2.8±0.4 ^{b,d,f}	2.6±0.4 ^{b,d}
interstitial inflammation	0	1.0±0.5 ^b	1.8±0.9 ^{b,d}	1.6±1.1 ^{b,d}

Data are means ± SD or n (%). eGFR was calculated using the Modification of Diet in Renal Disease formula. Student t test was used to determine the statistical significance between groupse .

The degree of sclerosis, thickening, and fibrosis were evaluated on the basis of an arbitrary scale (0 = normal = 0%, 1 = mild =,20%, 2 = moderate =20–40%, and 3 = severe = .40%) and was taken from routine pathological evaluations

Vascular sclerosis: 0 = normal; 1 = mild; 2 = moderate; and 3 = severe. a P < 0.05 vs Normal

Lumen cells and lumen thrombi: 0 = normal and 1 = increased. b P < 0.001 vs Normal

Mesangial matrix: 0 = normal; 1 = focal; 2 = increased, mild; and 3 = increased,nodular. d P < 0.01 vs Slow vs fast

Bowman's capsule thickening: 0 = normal; 1 = focal; 2 = circumferential e P < 0.05 vs CKD5

Interstitial fibrosis 0-no inflamation 1-mild 2-severe. f P < 0.05 vs CKD5

interstitial inflammation 0-no inflammation 1-mild 2-severe. h P < 0.001 vs CKD5

Supplementary Table 2: Primer Sequences used for RT-QPCR

	Forward primer sequences	Reverse primer sequences
mTGR5	5'-TGCTTCTTCCTAAGCCTACTACT	5'-CTGATGGTTCCGGCTCCATAG
mSIRT1	5'-TGATTGGCACCGATCCTCG	5'-CCACAGCGTCATATCATCCAG
mSIRT3	5'-GAGCGGCCTCTACAGCAAC	5'- GGAAGTAGTGAGTGACATTGGG
mERR α	5'-CAGGGAGGGAAGGGATGG	5'-TGAGGAGAGGAGCGAAGG
mNrf-1	5'- AGTATGCTAAGTGCTGATGAAGAC	5'-GCTGCCGTGGAGTTGAGG
mNrf-2	5'-CTTTAGTCAGCGACAGAAGGAC	5'- AGGCATCTTGTTTGGGAATGTG
mDGAT1	5'- CTGATCCTGAGTAATGCAAGGTT	5'- TGGATGCAATAATCACGCATGG
mPPAR α	5'-TCGCTATCCAGGCAGAAGG	5'- AACAACAACAATAACCCACAGACC
mUCP2	5'-CAGCGCCAGATGAGCTTTG	5'-GGAAGCGGACCTTTACCACA
mCPT1b	5'-TGTTAGAGAACGATAAGG	5'-CGCATTATTCAAGAAGAG
hSOD2	5'-CTGGAACCTCACATCAAC	5'-GTACTTCTCCTCGGTGAC
hLCAD	5'-AAGTGATGTTGTGATTGTAGTTG	5'-GAATAGTTCTGCGGTATCCTG
hCPT1b	5'-ATCTTCTTCTTCCGCCAAA	5'-GGTCAAGTTGCTGGTCTT
hPPAR α	5'-CAGATGCCACCAGGAGAAC	5'-TGAGGAGACCACAGGAACC